SCUTARI, ROSSANA
 Distribuzione geografica
Continente #
NA - Nord America 2.358
EU - Europa 313
AS - Asia 52
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 2.727
Nazione #
US - Stati Uniti d'America 2.355
IT - Italia 118
IE - Irlanda 87
CN - Cina 34
DE - Germania 23
SE - Svezia 19
BE - Belgio 15
GB - Regno Unito 15
FR - Francia 13
FI - Finlandia 9
KR - Corea 6
RU - Federazione Russa 6
UA - Ucraina 5
IN - India 4
IQ - Iraq 4
CA - Canada 3
HK - Hong Kong 2
AU - Australia 1
BG - Bulgaria 1
CL - Cile 1
ES - Italia 1
EU - Europa 1
JP - Giappone 1
NL - Olanda 1
SG - Singapore 1
ZW - Zimbabwe 1
Totale 2.727
Città #
Wilmington 620
Houston 571
Chandler 203
Fairfield 166
Woodbridge 158
Ann Arbor 66
Seattle 64
Cambridge 56
Dublin 54
Rome 53
New York 52
Ashburn 49
Medford 37
Dearborn 29
Lawrence 18
Brussels 15
San Diego 14
Cedarhurst 13
Beijing 12
Creede 12
Milan 12
Menlo Park 10
Palo Alto 9
Florence 7
Helsinki 7
Redwood City 7
La Veta 6
Santa Clara 5
Seoul 5
Mountain View 4
Albano Laziale 3
Baghdad 3
Colorado Springs 3
Council Bluffs 3
Engelhard 3
Verona 3
Wuhan 3
Atlanta 2
Bollate 2
Bologna 2
Cesano Maderno 2
Chiswick 2
Città Sant'Angelo 2
Genoa 2
Guangzhou 2
Hong Kong 2
Hounslow 2
Jacksonville 2
Kunming 2
London 2
Manitou Springs 2
Nanchang 2
Nanjing 2
St. George 2
Toronto 2
A Coruña 1
Amsterdam 1
Anagni 1
Billings 1
Chongqing 1
Clearwater 1
Düsseldorf 1
Falls Church 1
Hangzhou 1
Harare 1
Hebei 1
Hefei 1
Hyderabad 1
Jiaxing 1
Jinan 1
Kemerovo 1
Kilburn 1
Lappeenranta 1
Los Angeles 1
Melbourne 1
Mülheim 1
Nandyal 1
New Bedfont 1
Norwalk 1
Noto 1
Nuremberg 1
Padula 1
Phoenix 1
Prescot 1
Redmond 1
Rochester 1
Rozzano 1
Saint Petersburg 1
San Francisco 1
San Severo 1
Shenyang 1
Sofia 1
Stockholm 1
Suri 1
Vancouver 1
Zhengzhou 1
Totale 2.432
Nome #
The role of HIV infection in neurologic injury 366
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. 309
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 291
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets 278
Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success 235
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy 189
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 154
The degree of HIV-1 amino acid variability is strictly related to different disease progression rates 147
Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation 110
Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis 91
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 85
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 78
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control 64
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 59
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 54
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 48
SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021 42
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B 39
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 39
Impact of analytical treatment interruption on burden and diversification of HIV peripheral reservoir: a pilot study 38
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 31
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 23
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen 17
Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing. 14
An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein. 13
HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection 11
The transactivation of endogenous retroviruses correlates with HIV reservoir, lymphocytes activation and low CD4 count in virologically suppressed patients 10
HUMAN ENDOGENOUS RETROVIRUSES EXPRESSION CORRELATES WITH HIV RESERVOIR, LYMPHOCYTES ACTIVATION AND LOW CD4 COUNT IN VIROLOGICALLY SUPPRESSED PATIENTS 7
Amino acid variability of small molecule inhibitors and mAbs target sites in globally circulating RSV strains 4
HIV DNA viral reservoirs in blood and gut-associated lymphoid tissues (GALT): Implications of switch from triple antiretroviral therapy (ART) to 2-drug dolutegravir/lamivudine regimens 3
Totale 2.849
Categoria #
all - tutte 8.998
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.998


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019163 0 0 0 0 0 0 0 0 0 48 65 50
2019/2020838 71 59 43 88 74 89 83 75 80 64 54 58
2020/2021601 48 54 58 59 58 91 106 70 8 26 13 10
2021/2022314 16 9 2 15 15 21 30 26 106 15 8 51
2022/2023476 42 54 41 52 61 70 26 54 44 11 15 6
2023/2024197 43 4 20 13 21 44 10 3 11 28 0 0
Totale 2.849